BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
BIOMERICA INC
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026
$1.76−0.09 (-4.86%)
Close on Oct 19, 2026
- Market cap
- $5.80M
- P/E (TTM)
- –
- Dividend yield
- –
Biomerica statistics
Financials through Aug 31, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Biomerica | Industry median |
|---|---|---|
| Market Cap | $8.09M | $164.85M |
| Enterprise Value | $5.36M | $87.06M |
| PS Ratio | 1.87 | 3.60 |
| PB Ratio | 2.22 | 2.03 |
| P/TBV Ratio | 2.35 | 2.31 |
Enterprise value
| Measure | Biomerica | Industry median |
|---|---|---|
| EV / Sales | 1.24 | 2.43 |
Income (trailing twelve months)
| Measure | Biomerica | Industry median |
|---|---|---|
| Revenue | $4.34M | $57.94M |
| Gross Profit | $39.00K | $90.47M |
| Operating Income | -$5.43M | -$21.44M |
| Pretax Income | -$4.98M | -$14.45M |
| Net Income | -$5.01M | -$22.46M |
| EBITDA | -$5.36M | -$16.91M |
| EPS (Diluted) | -$1.63 | -$0.83 |
Margins
| Measure | Biomerica | Industry median |
|---|---|---|
| Gross Margin | 0.90% | 52.3% |
| Operating Margin | -125.2% | -44.5% |
| Pretax Margin | -114.9% | -13.0% |
| Profit Margin | -115.5% | -39.2% |
| EBITDA Margin | -123.6% | -31.3% |
Returns
| Measure | Biomerica | Industry median |
|---|---|---|
| Return on Equity (ROE) | -113.8% | -53.1% |
| Return on Assets (ROA) | -67.1% | -41.0% |
| Return on Invested Capital (ROIC) | -284.4% | -32.0% |
| Return on Capital Employed (ROCE) | -103.8% | -37.8% |
Growth
| Measure | Biomerica | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -11.2% | 6.01% |
| Revenue Growth (3Y CAGR) | -5.87% | 2.25% |
| Revenue Growth (5Y CAGR) | -9.16% | 6.42% |
Balance sheet
| Measure | Biomerica | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.73M | $62.42M |
| Net Cash (Debt) | $2.73M | $15.68M |
| Net Cash Per Share | $0.59 | $0.66 |
| Equity (Book Value) | $3.65M | $48.79M |
| Book Value Per Share | $0.79 | $1.36 |
| Tangible Book Value | $3.44M | $23.06M |
| Working Capital | $2.57M | $75.77M |
Financial position
| Measure | Biomerica | Industry median |
|---|---|---|
| Current Ratio | 1.91 | 3.30 |
| Quick Ratio | 1.28 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Biomerica | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.96M | -$12.35M |
Efficiency
| Measure | Biomerica | Industry median |
|---|---|---|
| Asset Turnover | 0.58 | 0.38 |
| Inventory Turnover | 2.77 | 2.67 |
| Revenue Per Employee | $255.12K | $398.96K |
| Profits Per Employee | -$294.65K | -$703.34K |
| Employee Count | 17 | 74 |
Dividends and yields
| Measure | Biomerica | Industry median |
|---|---|---|
| Earnings Yield | -61.9% | -22.7% |
| Buyback Yield | -39.1% | -0.73% |
| Shareholder Yield | -39.1% | 0.00% |
Shares
| Measure | Biomerica | Industry median |
|---|---|---|
| Shares Outstanding | 4,598,970 | 58,179,650 |
| Shares Change (YoY) | 31.3% | 11.1% |
| Shares Change (QoQ) | 43.9% | 0.54% |
| Float | 3,338,890 | 49,173,100 |
| Shares Held by Insiders | 27.4% | 11.6% |
| Shares Held by Institutions | 2.72% | 59.4% |
Taxes
| Measure | Biomerica | Industry median |
|---|---|---|
| Income Tax | $25.00K | $91.50K |
Scores
| Measure | Biomerica | Industry median |
|---|---|---|
| Altman Z-Score | -10.29 | -0.24 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.07 | -2.62 |
Calculated by StockData from Biomerica's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.